IP Library Granted Patent US 8,420,120
Granted Patent B2
US 8,420,120 · App. 13/366,168 · Granted Apr 16, 2013

Oral drug delivery system

Inventors: Su Il Yum (Los Altos, CA); Grant Schoenhard (San Carlos, CA); Arthur J. Tipton (Birmingham, AL); John W. Gibson (Springville, AL); John C. Middleton (Fort Collins, CO)
Assignee: Durect Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,420,120
App. No.
13/366,168
Granted
Apr 16, 2013
Kind
B2
Abstract

Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.

Claims (40)

1. A formulation comprising:

an opioid;

sucrose acetate isobutyrate (SAIB);

a cellulose acetate butyrate (CAB) having at least one feature selected from a butyryl content ranging from about 17% to about 38%, an acetyl content ranging from about 13% to about 30%, and a hydroxyl content ranging from about 0.8% to about 1.7%; and

a solvent.

2. The formulation of claim 1 , wherein the opioid comprises a member selected from buprenorphine, butorphanol, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, oxymorphone, and tramadol, or a pharmacologically effective salt thereof.

3. The formulation of claim 1 , wherein the opioid is hydrocodone, hydromorphone, levorphanol, morphine, oxymorphone, or oxycodone.

4. The formulation of claim 1 , wherein the opioid comprises oxycodone.

5. The formulation of claim 1 , wherein the formulation comprises from about 20 weight percent to about 90 weight percent of the SAIB.

6. The formulation of claim 1 , wherein the formulation comprises from about 1 weight percent to about 8.6 weight percent of the CAB.

7. The formulation of claim 1 , wherein the formulation comprises from about 20 weight percent to about 50 weight percent of the solvent.

8. The formulation of claim 1 , wherein the solvent comprises propylene carbonate, N-methylpyrrolidone (NMP), glycofurol, alpha-tocopherol, diethyl phthalate, or polyethylene glycol 400 (PEG 400).

9. The formulation of claim 1 , wherein the solvent comprises triacetin or ethyl lactate.

10. The formulation of claim 1 , wherein the solvent comprises triacetin.

11. The formulation of claim 1 , further comprising a member selected from caprylic/capric triglyceride, isopropyl myristate (IPM), ethyl oleate, dimethyl phthalate, and benzyl benzoate.

12. The formulation of claim 1 , further comprising isopropyl myristate (IPM).

13. The formulation of claim 12 , wherein the formulation comprises from about 1 weight percent to about 75 weight percent of the IPM.

14. The formulation of claim 12 , wherein the formulation comprises:

from about 20 weight percent to about 90 weight percent of the SAIB;

from about 1 weight percent to about 8.6 weight percent of the CAB;

from about 1 weight percent to about 75 weight percent of the IPM; and

from about 20 weight percent to about 50 weight percent of the solvent.

15. The formulation of claim 14 , wherein the formulation comprises from 3 weight percent to 7.8 weight percent of the CAB.

16. The formulation of claim 14 , wherein the formulation comprises from 0.1 weight percent to 10 weight percent of the IPM.

17. The formulation of claim 14 , wherein the formulation comprises:

from about 30 weight percent to about 70 weight percent of the SAIB;

from about 1 weight percent to about 8.6 weight percent of the CAB;

from about 1 weight percent to about 75 weight percent of the IPM; and

from about 25 weight percent to about 48 weight percent of the solvent.

18. The formulation of claim 1 , further comprising an antioxidant.

19. The formulation of claim 1 , further comprising butylhydroxyl toluene.

20. The formulation of claim 1 , wherein the formulation is contained in a capsule.

21. The formulation of claim 20 , wherein the capsule comprises gelatin or hydroxyl propylmethyl cellulose.

22. The formulation of claim 20 , wherein the capsule comprises a hard capsule comprising gelatin or hydroxyl propylmethyl cellulose.

23. A method of providing pain relief to a subject in need thereof, the method comprising:

orally administering to the subject an effective amount of the formulation of claim 20 .

24. A method of providing pain relief to a subject in need thereof, the method comprising:

orally administering to the subject an effective amount of the formulation of claim 1 .

25. The formulation of claim 1 , wherein the opioid comprises oxycodone or a pharmacologically effective salt thereof.

26. The formulation of claim 1 , wherein the opioid comprises a salt of oxycodone.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2014
From: FU, ROGER; ZAMLOOT, MICHAEL S.
To: PAIN THERAPEUTICS, INC.
Reel/Frame 034531/0738 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2014
From: PAIN THERAPEUTICS, INC.
To: DURECT CORPORATION
Reel/Frame 034531/0762 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2012
From: YUM, SU IL; SCHOENHARD, GRANT; TIPTON, ARTHUR J.; GIBSON, JOHN W.; MIDDLETON, JOHN C.
To: DURECT CORPORATION
Reel/Frame 027681/0872 →
Continuity (4)
Continuation 10737144 · Dec 15, 2003
Provisional Application 60433116 · Dec 13, 2002
Provisional Application 60517464 · Nov 4, 2003
Related Publication 20120135073A1 · May 31, 2012